Market capitalization | $275.44m |
Enterprise Value | $232.88m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 4.08 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-36.93m |
Cash position | $54.85m |
EPS (TTM) EPS | $-0.46 |
P/S forward | 847.51 |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
4 Analysts have issued a Alpha Tau Medical forecast:
4 Analysts have issued a Alpha Tau Medical forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -37 -37 |
4%
4%
|
Net Profit | -32 -32 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.
Head office | Israel |
CEO | Uzi Sofer |
Employees | 112 |
Founded | 2015 |
Website | www.alphatau.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.